The Difficult Management of Depressive Symptoms in a Patient with Myasthenia Gravis: A Case Report

Abstract

Introduction: Depression in patients with Myasthenia Gravis (MG) can be multifactorial, involving biological, psychological, and social factors. Depressive manifestations may arise as a result of the emotional impact of a chronic and potentially disabling condition, as well as from neurobiological changes associated with the disease or immunosuppressive treatment. Method: In this article, we report a case of a 51-year-old man diagnosed with MG and concomitant depressive symptoms. Treatment was initiated with sertraline 150 mg/day and trazodone 50 mg/day. Results: The choice of psychotropics should be made with caution, opting for drugs with a lower likelihood of affecting neuromuscular function. SSRIs are the most effective drugs for treating depression in patients with MG, and it is advisable to avoid drugs with anticholinergic effects, such as tricyclics and haloperidol. Conclusion: Caution is important when prescribing psychotropic medications to patients with MG due to the risk of affecting neuromuscular transmission